Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1909 5
1910 3
1913 1
1914 4
1915 1
1916 1
1917 2
1918 4
1919 1
1921 3
1922 1
1926 2
1931 1
1932 2
1938 1
1949 1
1952 1
1962 1
1963 1
1965 3
1966 1
1969 4
1970 3
1971 4
1972 3
1973 4
1974 6
1975 2
1976 2
1977 3
1978 1
1979 1
1980 2
1981 4
1982 3
1983 2
1984 3
1985 3
1986 2
1987 5
1988 3
1989 3
1990 5
1991 3
1992 4
1993 5
1994 3
1995 2
1996 5
1997 4
1998 3
1999 2
2000 4
2001 2
2002 4
2003 6
2004 5
2005 3
2006 10
2007 7
2008 10
2009 18
2010 8
2011 8
2012 8
2013 10
2014 6
2015 6
2016 16
2017 9
2018 11
2019 6
2020 8
2021 5
2022 3
2023 2
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

298 results

Results by year

Filters applied: . Clear all
Page 1
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV Jr, Dieleman LA, Katz S, Rutgeerts P; UNITI–IM-UNITI Study Group. Feagan BG, et al. N Engl J Med. 2016 Nov 17;375(20):1946-1960. doi: 10.1056/NEJMoa1602773. N Engl J Med. 2016. PMID: 27959607 Free article. Clinical Trial.
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P; SONIC Study Group. Colombel JF, et al. N Engl J Med. 2010 Apr 15;362(15):1383-95. doi: 10.1056/NEJMoa0904492. N Engl J Med. 2010. PMID: 20393175 Free article. Clinical Trial.
Among giants.
Fleisher MR. Fleisher MR. Inflamm Bowel Dis. 2013 Sep;19(10):E82. doi: 10.1097/MIB.0b013e318299c9aa. Inflamm Bowel Dis. 2013. PMID: 23846490 No abstract available.
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.
Pietanza MC, Waqar SN, Krug LM, Dowlati A, Hann CL, Chiappori A, Owonikoko TK, Woo KM, Cardnell RJ, Fujimoto J, Long L, Diao L, Wang J, Bensman Y, Hurtado B, de Groot P, Sulman EP, Wistuba II, Chen A, Fleisher M, Heymach JV, Kris MG, Rudin CM, Byers LA. Pietanza MC, et al. Among authors: fleisher m. J Clin Oncol. 2018 Aug 10;36(23):2386-2394. doi: 10.1200/JCO.2018.77.7672. Epub 2018 Jun 15. J Clin Oncol. 2018. PMID: 29906251 Free PMC article. Clinical Trial.
Fenfluramine overdosage.
Fleisher MR, Campbell DB. Fleisher MR, et al. Lancet. 1969 Dec 13;2(7633):1306-7. Lancet. 1969. PMID: 4188015 No abstract available.
Randomized Trial of Facilitated Adherence to Screening Colonoscopy vs Sequential Fecal-Based Blood Test.
Zauber AG, Winawer SJ, O'Brien MJ, Mills GM, Allen JI, Feld AD, Jordan PA, Fleisher M, Orlow I, Meester RGS, Lansdorp-Vogelaar I, Rutter CM, Knudsen AB, Mandelson M, Shaukat A, Mendelsohn RB, Hahn AI, Lobaugh SM, Soto Palmer B, Serrano V, Kumar JR, Fischer SE, Chen JC, Bayuga-Miller S, Kuk D, O'Connell K, Church TR. Zauber AG, et al. Among authors: fleisher m. Gastroenterology. 2023 Jul;165(1):252-266. doi: 10.1053/j.gastro.2023.03.206. Epub 2023 Mar 21. Gastroenterology. 2023. PMID: 36948424 Clinical Trial.
Reply to C. Ren et al.
Heller G, McCormack R, Kheoh T, Molina A, Smith MR, Dreicer R, Saad F, de Wit R, Aftab DT, Hirmand M, Limon-Carrera A, Fizazi K, Fleisher M, de Bono JS, Scher HI. Heller G, et al. Among authors: fleisher m. J Clin Oncol. 2018 Aug 1;36(22):2354-2356. doi: 10.1200/JCO.2018.78.2672. Epub 2018 Jun 12. J Clin Oncol. 2018. PMID: 29894273 No abstract available.
Circulating tumor cells as biomarkers in prostate cancer.
Danila DC, Fleisher M, Scher HI. Danila DC, et al. Among authors: fleisher m. Clin Cancer Res. 2011 Jun 15;17(12):3903-12. doi: 10.1158/1078-0432.CCR-10-2650. Clin Cancer Res. 2011. PMID: 21680546 Free PMC article. Review.
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
Vermeire S, Lakatos PL, Ritter T, Hanauer S, Bressler B, Khanna R, Isaacs K, Shah S, Kadva A, Tyrrell H, Oh YS, Tole S, Chai A, Pulley J, Eden C, Zhang W, Feagan BG; LAUREL Study Group. Vermeire S, et al. Lancet Gastroenterol Hepatol. 2022 Jan;7(1):28-37. doi: 10.1016/S2468-1253(21)00295-8. Epub 2021 Nov 17. Lancet Gastroenterol Hepatol. 2022. PMID: 34798037 Clinical Trial.
Homeopathy or isopathy?
Fleisher MA, McCarter DF. Fleisher MA, et al. J Fam Pract. 2002 Nov;51(11):984, 986; author reply 986. J Fam Pract. 2002. PMID: 12485561 No abstract available.
298 results